CDNA · Caredx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $379.81M | $333.79M | $280.32M | $321.79M | $296.40M | $192.19M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $71.43M | $72.41M | $81.87M | $90.39M | $76.53M | $48.94M |
| SG&A | $107.56M | $123.78M | $117.87M | $100.40M | $74.96M | $48.81M |
| Total Operating Expenses | $410.59M | $293.02M | $483.69M | $399.02M | $326.12M | $214.72M |
| D&A | $15.02M | $14.19M | $14.39M | $11.60M | $8.80M | $7.01M |
| Operating Income | ($30.78M) | $40.77M | ($203.36M) | ($77.23M) | ($29.73M) | ($22.53M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $271.0K | $310.0K | $141.0K | $379.0K | ($1.43M) | ($1.04M) |
| Net Income | ($21.35M) | $52.55M | ($190.28M) | ($76.61M) | ($30.66M) | ($18.71M) |
| EPS - Basic | ($0.40) | $1.00 | ($3.54) | ($1.44) | ($0.59) | ($0.40) |
| EPS - Diluted | ($0.40) | $0.93 | ($3.54) | ($1.44) | ($0.59) | ($0.40) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.43M | $114.69M | $82.20M | $89.92M | $348.49M | $134.67M |
| Accounts Receivable | $42.63M | $64.61M | $51.06M | $66.31M | $59.76M | $34.62M |
| Inventory | $26.70M | $19.50M | $19.47M | $19.23M | $17.19M | $10.01M |
| Accounts Payable | $9.99M | $7.69M | $12.87M | $9.94M | $13.34M | $9.65M |
| Current Assets | $257.13M | $351.83M | $313.71M | $387.85M | $433.36M | $273.10M |
| Total Assets | $413.23M | $491.05M | $466.83M | $542.99M | $566.62M | $368.51M |
| Current Liabilities | $89.85M | $89.37M | $78.07M | $75.97M | $77.30M | $69.22M |
| Long-term Debt | - | - | - | - | - | $0 |
| Total Liabilities | $110.13M | $112.62M | $205.50M | $112.08M | $100.75M | $90.83M |
| Stockholders' Equity | $303.10M | $378.43M | $261.33M | $430.91M | $465.88M | $277.68M |
| Retained Earnings | ($735.36M) | ($626.24M) | ($678.27M) | ($460.44M) | ($383.19M) | ($352.53M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $42.03M | $38.05M | ($18.39M) | ($25.24M) | ($19.29M) | $33.43M |
| Investing Cash Flow | $2.16M | ($483.0K) | $40.45M | ($228.50M) | $47.71M | ($100.39M) |
| Financing Cash Flow | ($93.39M) | ($5.61M) | ($29.61M) | ($4.54M) | $185.64M | $163.15M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -8.1% | 12.2% | -72.5% | -24.0% | -10.0% | -11.7% |
| EBITDA margin | -4.2% | 16.5% | -67.4% | -20.4% | -7.1% | -8.1% |
| Net margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | 18.8% | 21.7% | 29.2% | 28.1% | 25.8% | 25.5% |
| SG&A / Revenue | 28.3% | 37.1% | 42.0% | 31.2% | 25.3% | 25.4% |
| Effective tax rate | - | 0.6% | - | - | - | - |
| Return on assets | -5.2% | 10.7% | -40.8% | -14.1% | -5.4% | -5.1% |
| Return on equity | -7.0% | 13.9% | -72.8% | -17.8% | -6.6% | -6.7% |
| Return on invested capital | - | - | - | - | - | -6.4% |
| Liquidity | ||||||
| Current ratio | 2.86 | 3.94 | 4.02 | 5.10 | 5.61 | 3.95 |
| Quick ratio | 2.56 | 3.72 | 3.77 | 4.85 | 5.38 | 3.80 |
| Cash ratio | 0.73 | 1.28 | 1.05 | 1.18 | 4.51 | 1.95 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.36 | 1.30 | 1.79 | 1.26 | 1.22 | 1.33 |
| Liabilities / Assets | 0.27 | 0.23 | 0.44 | 0.21 | 0.18 | 0.25 |
| Efficiency | ||||||
| Asset turnover | 0.92 | 0.68 | 0.60 | 0.59 | 0.52 | 0.52 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 41d | 71d | 66d | 75d | 74d | 66d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | 23.0x | - | - | - | - |
| P / B | 3.3x | 3.2x | 2.5x | 1.4x | 5.1x | 12.1x |
| P / S | 2.6x | 3.6x | 2.3x | 1.9x | 8.0x | 17.5x |
| EV / EBITDA | - | 20.0x | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 13.8% | 19.1% | -12.9% | 8.6% | 54.2% | 51.3% |
| Revenue CAGR (3y) | 5.7% | 4.0% | 13.4% | 36.3% | 93.9% | 58.4% |
| Revenue CAGR (5y) | 14.6% | 21.3% | 47.2% | 46.1% | 48.8% | 46.8% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | -163.3% | -159.8% | -32.0% | 8.2% |
| Net income growth (YoY) | - | - | -148.4% | -149.9% | -63.8% | 14.8% |
| EPS growth (YoY) | - | - | -145.8% | -144.1% | -47.5% | 23.1% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -19.9% | 44.8% | -39.4% | -7.5% | 67.8% | 180.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$379.81M totalReportable Segment$379.81M · 100.0%
Product / service
$379.81M totalService$274.50M · 72.3%
Patient And Digital Solutions$56.93M · 15.0%
Product$48.38M · 12.7%
Geographic
$379.81M totalUS$359.94M · 94.8%
Non Us$19.87M · 5.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.62
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing CareDx against the 5 most active filers in the same SIC group.